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To develop novel strategies for prevention and treatment of dyslipidemia, it is essential
to understand the pathophysiology of dyslipoproteinemia in humans. Lipoprotein
metabolism is a complex system in which abnormal concentrations of various lipoprotein
particles can result from alterations in their rates of production, conversion, and/or
catabolism. Traditional methods that measure plasma lipoprotein concentrations only
provide static estimates of lipoprotein metabolism and hence limited mechanistic
information. By contrast, the use of tracers labeled with stable isotopes andmathematical
modeling, provides us with a powerful tool for probing lipid and lipoprotein kinetics in vivo
and furthering our understanding of the pathogenesis of dyslipoproteinemia.
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INTRODUCTION
The most abundant lipids in plasma are: triglycerides, cholesterol, cholesterol esters, and
phospholipids. Since lipids are water-insoluble they have to be transported in lipoprotein particles.
They consist of a hydrophobic core of triglycerides and cholesterol esters, shielded from the water
by a surface monolayer of phospholipids, unesterified cholesterol, and specific proteins (Mahley
et al., 1984). The protein components of the lipoprotein are known as apolipoproteins (apo)
(Mahley et al., 1984). The amount of lipids and proteins in the lipoprotein particles affect their
density—the lower the density of a lipoprotein, the more lipids it contains relative to protein.
Depending on function and hydrated density, the lipoproteins are traditionally divided into
four major classes. These are chylomicrons, very low-density lipoproteins (VLDL), low-density
lipoproteins (LDL), and high-density lipoprotein (HDL).
Chylomicrons and VLDL particles are the major carriers of triglycerides in the circulation.
Chylomicrons are synthesized in the intestine and carry dietary lipids absorbed by the intestine.
VLDL particles are synthesized by the liver. The function of these lipoprotein particles is to
transport and deliver triglycerides to adipose tissue and muscles. Elevated triglycerides in plasma
are associated with increased risk for cardiovascular disease (CVD).
In order to prevent and treat disturbances in metabolism of triglyceride-rich lipoproteins,
it is necessary to clarify the underlying mechanism(s). The hypertriglyceridemia can either be
caused by increased secretion, conversion, or catabolism of lipoprotein particles of triglyceride-rich
lipoproteins. Although static s measurements of plasma lipids and functional assays may give some
information, in the end, it is necessary to study the true unit of function (the integrated metabolic
Adiels et al. In vivo Kinetics of VLDL
pathway) to understand the complexity of lipoprotein
metabolism (Chan et al., 2004a,b; Adiels et al., 2008). Therefore,
kinetic studies with stable isotopes are critical to explore and
clarify the pathophysiology of lipid disorders in humans (Chan
et al., 2004a,b; Adiels et al., 2008). The aim of this review is to
illustrate how kinetic studies have furthered our understanding
of impaired human lipoprotein metabolism.
METABOLISM OF apoB-CONTAINING
LIPOPROTEINS
Triglyceride-rich lipoproteins in the circulation are a mixture of
chylomicrons (synthesized in the intestine) and VLDL particles
(synthesized in the liver) (Figure 1). Each of these lipoproteins
contains one molecule of apolipoprotein B (apoB). apoB is a
large hydrophobic protein that remains bound to the lipoprotein
particles (Segrest et al., 2001). This unique characteristic of apoB
makes it possible to use apoB as a tool to trace the intravascular
kinetics of the triglyceride-rich lipoproteins.
apoB is present in two different lengths; apoB100 and apoB48.
The shorter form apoB48 corresponds to the amino-terminal
48% of apoB100. It is in humans exclusively synthesized in the
intestine, and thus present on intestinal-derived chylomicrons
and their remnants. The longer form, apoB100 is synthesized in
the liver and present on VLDL, IDL, and LDL. Both apoB100
and apoB48 are coded by the same gene, but the shorter apoB48
is generated as a result of a posttranscriptional process called
“RNA editing” that converts a cytidine-to-uridine (C-to-U) that
generates a stop-codon and thus a truncated form of the full-
length protein. In humans, this posttranscriptional RNA editing
occurs in the intestine only but in certain animals such as rodents
and dogs, the process occurs also in the liver (Powell et al., 1987).
Why is apoB48 synthesized by this complex mechanism in the
Intestine? The explanation is still unclear but it has been shown
that apoB48-containing lipoproteins can carry more lipids than
apoB100-containing lipoproteins. This is important since the
chylomicrons must have capacity to rapidly and efficiently absorb
large amounts of dietary lipids and a meal (Hussain, 2014). Once
synthesized, chylomicrons are secreted into the lymphatic vessels
until they enter into the bloodstream close to the heart. Thus, they
are delivered directly to adipose tissue and muscles without first
being metabolized by the liver. In the circulation, chylomicron-
triglycerides are hydrolyzed by the enzyme lipoprotein lipase,
which is present on the endothelial cells in the heart, muscle,
and adipose tissue. The released free fatty acids are then taken up
these tissues where they are stored or used for energy production.
The regulation is LPL is controlled transcriptionally and post-
transcriptionally. On the endothelial cells, LPL is activated by
apoC-II and inhibited by apoC-III and ANGPTL4.
When the triglycerides are removed from the hydrophobic
core of the chylomicrons, they shrink in size and become
chylomicron remnants. The smaller chylomicron remnants are
cleared from the circulation by the liver (Mahley and Ji,
1999; MacArthur et al., 2007; Williams, 2008; Williams and
Chen, 2010). Recent studies have shown that chylomicron
remnants are atherogenic and directly involved in atherogenesis.
The explanation for this is that chylomicrons in addition
to triglycerides also contain some cholesterol esters. When
triglycerides are removed from the lipoprotein particle, the
cholesterol esters remain. Thus, the chylomicron remnants
become enriched in cholesteryl esters.
The liver secretes apoB100-containing VLDL particles. In fact,
the liver produces two different forms of VLDL; larger VLDL1
and smaller VLDL2 particles. The triglyceride-rich VLDL1
particles carry most of the plasma triglycerides and have been
shown to be the major determinant for the variation of plasma
triglycerides in both healthy subjects and individuals with type
2 diabetes (Hiukka et al., 2005; Boren et al., 2014; Taskinen and
Boren, 2015). The formation of VLDL1 is highly associated with
fatty liver (Adiels et al., 2008; Boren et al., 2013). Indeed, subjects
with non-alcoholic fatty live disease (NAFLD) have increased
VLDL1 production (Adiels et al., 2006b).
VLDL-triglycerides are hydrolyzed by the same LPL-
dependent mechanisms as chylomicrons, Figure 1. As
VLDL-triglycerides are hydrolyzed, the density of the lipoprotein
increases and they become intermediate density lipoproteins
(IDL) and subsequently LDL. Like chylomicrons, also VLDL
contains mainly triglycerides but also some cholesterol esters
that become enriched in the lipoprotein particle when the
triglycerides are removed. Thus, the end-product of the lipolytic
cascade, LDL contains mainly cholesterol esters and is the major
determinant of cholesterol in plasma. LDL particles are removed
from the circulation by the LDL-receptor on the hepatocytes. The
importance of the LDL-receptor for clearance of LDL particles is
illustrated by the genetic disorder, familial hypercholesterolemia
caused by mutation in the LDL-receptor. The disease is
associated with hypercholesterolemia and premature CVD.
Patients with obesity and insulin resistance have a
characteristic atherogenic dyslipidemia characterized by
increased plasma triglycerides, excessive postprandial lipemia
(i.e., rise in triglyceride-rich lipoproteins after eating)
postprandial hyperlipidemia, and low concentrations of HDL
cholesterol (Taskinen, 2003; Adiels et al., 2006a). Interestingly,
these lipid disturbances are not isolated abnormalities but
metabolically linked to each other (Taskinen, 2005), and they
appear years before type 2 diabetes is diagnosed (Taskinen, 2003).
PRINCIPLES OF TRACER METHODOLOGY
To simplest approach to study the kinetics of a molecule (i.e.,
the tracee) is to introduce the same molecule (tracer), but
labeled into the system (Chan et al., 2004a,b). This process has
many advantages but also obvious concerns, especially in human
studies. The alternative is to introduce a labeled precursor of the
molecule of interest. Ideally, the tracer should be easily detected
and quantified, and not affect the system. Usually, kinetic studies
are performed in a steady-state, where the rates of input and
output for a given unlabeled tracee substance are equal and time-
invariant. Thus, the information provided by the tracer reflects
the behavior of the tracee (Barrett et al., 2006). At various times,
the amount of tracer is quantified to provide a kinetic curve.
Then a mathematical model is constructed to extract all of the
information contained in the kinetic curve. By fitting a model
to the data, it is possible to calculate the parameters of the
model that characterize the flux of molecules between kinetically
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FIGURE 1 | Fasting and post-prandial triglyceride metabolism. In fasting, apoB100 containing lipoproteins are secreted from the liver and are hydrolyzed by
lipoprotein lipase (LpL) to form smaller and denser particles. Hence, very low density lipoprotein (VLDL)1 particles become VLDL2 particles and VLDL2 particles
become intermediate density lipoproteins (IDL). After remodeling with cholesterol ester transfer protein and hepatic lipase the end product are the low density
lipoproteins (LDL). In the post-prandial phase, the intestine secretes triglyceride rich apoB48 containing lipoproteins, the chylomicrons. After hydrolyzation by LpL,
large and small chylomicron remnants (CMR) are formed. This process likely occupies the majority of available LpL, thus resulting in slower turn-over of the apoB100
containing lipoproteins and causing an accumulation of these lipoproteins.
homogeneous pools of molecules. Historically, the radioactive
isotopes were used as tracers, but today naturally occurring
non-radioactive stable isotopes are almost exclusively used in
human studies. The technical advances in mass-spectrometry
technologies now permit accuratemeasurement of stable isotopes
in smaller samples and in low concentrations (Barrett et al., 2006;
Adiels et al., 2010).
A tracer can be introduced into the system either as a bolus
injection or as a constant infusion given immediately after a
priming dose. The bolus administration of the tracer is suitable to
study kinetics of molecules with a relatively slow rate of turnover
since the enrichment curves (the tracer/tracee ratios) after a bolus
injection corresponds to the impulse response of the system.
Furthermore, it also enables determination of newly synthesized
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particles, since the intracellular precursor enrichment is greater
at the start of the study. Primed constant infusions require a
longer time to achieve a plateau of isotopic enrichment but can be
appropriate for kinetic studies of molecules with rapid turnover.
MODELING OF LIPOPROTEIN METBOLISM
Mathematical modeling enables us to better understand
experimental observations. Predictions derived from model
predictions can subsequently be experimentally tested. Toward
this goal, known pathways are described by a set of differential
equations, thereby allowing quantitative estimates to be derived.
In multi-compartment models, molecules of interest move
among different compartments of a system. Each compartment
is assumed to be a homogeneous entity within which the entities
being modeled are equivalent. Multicompartment modeling
has proven to yield predictions which are as accurate as those
made by physiological models, and the data required can be
derived from measurements of tracer/tracee ratios of stable
isotopes. Multicompartment models differ in how complex they
are. Practically, their design is usually a compromise for what is
practically feasible. Too simplified models may not adequately
describe the kinetic heterogeneity present within the system. On
the other hand, it’s hard to generate experimental data for overly
complex models.
The power of mathematical modeling to describe the
metabolic pathways of lipid and lipoprotein metabolism was
first demonstrated by Drs. Berman and Zech (Grundy et al.,
1979; Zech et al., 1979). Since then, kinetic studies combined
with mathematical modeling have been used to clarify the
pathogenesis of impaired lipoprotein metabolism in humans
linked to accelerated CVD, obesity, and insulin resistance
(Figure 2). The methodology has also been instrumental in
testing how efficiently novel drugs improve the dyslipidemia.
However, it’s important to emphasize that all models are
based on several assumptions and simplifications. Therefore,
mathematical modeling does not determine the kinetics of lipids
directly; rather, they derive an indirect approximation.
MODELS TO STUDY VLDL KINETICS
Increased levels of apoB-containing lipoproteins are the most
important risk-factor for developing CVD. It’s therefore clinically
relevant to decipher the pathophysiology of impairedmetabolism
of apoB-containing lipoproteins. Until today most studies have
used steady-statemodels to elucidate VLDL kinetics in the fasting
state. However, it can be argued that these studies are not fully
physiologically designed since human are in a postprandial state
most of the time awake.
To study postprandial lipid metabolism it is necessary to
include also intestinal derived lipoproteins. The majority of
studies of intestinal lipid metabolism has been conducted in
a “constant feeding” regime where small meals are served
frequently to achieve a steady state of the intestinal lipoprotein
secretion (Lamon-Fava et al., 2007; Sun et al., 2013; Padilla et al.,
2014; Tremblay et al., 2014; Xiao et al., 2014). To date, only
a few studies have focused on apoB48 metabolism following a
FIGURE 2 | Outline of kinetic tracer studies. In vivo kinetic studies are
complex and involve both extensive phenotyping of study subjects, clinical
studies where stable isotopes are infused into the study subjects and blood
samples are taken, isolation of lipoprotein fractions by ultracentrifugation,
enrichment studies of the stable isotopes using different mass spectroscopy
techniques, and mathematical modeling of the enrichment curves to derive
indices of kinetic variables.
single meal (Wong et al., 2014a,b). No studies have yet linked
hepatic and intestinal lipid metabolism in a combined model,
and therefore it is not possible to study the interaction of
these lipoproteins as depicted in Figure 1. From fat load studies
it is obvious that there is a clear interplay between hepatic
and intestinal lipoproteins (Adiels et al., 2012). Therefore, such
models must include that apoB48- and apoB100-containing
particles are cleared from the circulation by common pathways
and therefore compete for clearance (Brunzell et al., 1973).
During the postprandial phase, other factors need also to be
considered such as insulin secretion which may affect hepatic
lipoprotein secretion (Lewis et al., 1993; Adiels et al., 2007;
Sorensen et al., 2011; Sondergaard et al., 2012).
In steady-state modeling of VLDL kinetics it has been
discussed whether VLDL-apoB and VLDL-TG should be
modeled in the same integrated model, or if they should be
modeled independently. In integrated models the equation for
the rate of change of an apoB100 compartment is linked to the
rate of change of the corresponding triglyceride compartment
size. This procedure of tying together the apoB100 and
triglyceride models enhances the precision of the model as a
whole. As each particle contains one single copy of apoB100,
the model provides an estimate of the lipolytic rates (the loss
of triglycerides per time unit), which can then be used as a
physiological readout for answering study questions related to
dyslipidemia. Drs. Ramakrishnan andGinsberg recently reported
that the VLDL-apoB and VLDL-TG pools in the delipidation
cascade have identical rate constants despite different fates
and mass distribution (Ramakrishnan and Ginsberg, 2015).
These results strongly support integrated steady-state models of
VLDL-apoB and VLDL-TG kinetics.
The major predictor of plasma triglycerides are VLDL1-TG.
We therefore developed a multicompartment model that allows
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FIGURE 3 | Compartment model of VLDL apoB and triglyceride
kinetics. The model includes separate modules for leucine and glycerol.
Plasma leucine kinetics is modeled using a four-compartment system that
drives the synthesis and secretion of apoB into VLDL1 and VLDL2. Plasma
glycerol kinetics is modeled using a two-compartment system connected to
fast and slow pathways for triglyceride (TG) synthesis. Plasma apoB and
triglyceride kinetics are modeled using a four-compartment hydrolysis chain, in
which the kinetics of apoB and triglyceride coupled. For each apoB
compartment, there is an equivalent compartment for triglyceride. Triglycerides
hydrolyzed from VLDL particles are represented by the dashed arrows, and
particles lost from the plasma space are represented by the solid arrows. See
Adiels et al. (2005) for additional model details.
the kinetics of triglycerides and apoB100 in VLDL1 andVLDL2 to
be simultaneously assessed after a bolus injection of glycerol and
leucine stable isotopes (Figure 3) (Adiels et al., 2005). Analysis
of tracer/trace curves of the stable isotopes in VLDL1 and
VLDL2 was used to derive estimates of kinetic parameters using
mathematical modeling. By integrating apoB and triglycerides in
the model, the triglyceride: apoB ratio of newly produced VLDL1
and VLDL2 particles can be estimated to follow the transfer and
removal of lipids (Adiels et al., 2005).
The model can be envisioned as a two-layer model,
connected at certain points and is based on the apoB model
as described by Packard et al. (1995). The model consists
of four parts; plasma leucine, plasma glycerol, the assembly
of lipoprotein, and lipoprotein plasma kinetics. The plasma
kinetics is modeled by a four-compartment hydrolysis chain,
where the apoB and triglyceride kinetics are coupled at the
transfer between compartments. Removal from triglyceride
compartments consists of both removal of whole particles and
removal of triglycerides.
INDIVIDUAL AND POPULATION KINETICS
Traditionally, parameters for each individual are estimated
individually and conclusions are made based on some statistical
model applied to the model output. The model complexity
ranges from one single compartment models describing
VLDL-TG-kinetics (Patterson et al., 2002), to 12 compartments
describing the combined apoB and TG kinetics in VLDL1 and
VLDL2 (Adiels et al., 2005). The majority of published studies
have used the SAAMII software (The Epsilon Group, US)
(Barrett et al., 1998).
As models are becoming more complex and includes more
unknown parameters, more data is needed to support the
estimation of the model parameters. Individual data sets are
also sensitive to loss of data and data quality, which is directly
reflected in the variability in the estimated parameters.
Modernmodeling techniques combine the mechanistic model
(describing the system) with a statistical model (describing the
populations). This is an extension to non-linear mixed effects
models (NLME) where the non-linear model is the set of
ordinary differential equations describing the system. Model
parameters are described as random variables drawn from a
distribution centered round the population mean. Using data
from all individuals, population means and variances as well as
individual estimates are calculated for all parameters (Beal and
Sheiner, 1982).
The major gain using NLME approaches are that generally the
estimated variances are smaller compared to the traditional
approach, thus statistical power is greatly increased.
Furthermore, such methods have shown produce better
results also when data are sparse (Denti et al., 2009; Largajolli
et al., 2012). Using these techniques we have recently shown
that estimation of lipoprotein kinetics parameters can greatly be
improved by an NLME approach (Berglund et al., 2012) (leucine
subsystem) and (Berglund et al., 2015) (full system).
To estimate the day-to-day variability in VLDL kinetics and
other measures, Magkos et al. repeated a kinetic study in 8
obese men on two occasions 2 months apart (Magkos et al.,
2011). Using this data they calculated the sample size needed
to detect differences (15–35%) between two groups during an
intervention. For VLDL-TG secretion, n=15 was needed in each
group to detect a difference of 25% using an unpaired study
design at a study power of 80%. We compared 15 healthy
controls and 15 type 2 diabetic subjects and found that using
the traditional approach, n=9 was needed to detect the difference
in VLDL1 secretion. In contrast, using the NLME approach, a
sample size of only n=5 was needed to detect the same difference
(Berglund et al., 2015).
The limitations for these methods are so far that they are
very computational intensive and the methods are not yet
implemented in traditional software.
PATHOPHYSIOLOGY OF DYSLIPIPIDEMIA
IN OBESE SUBJECTS
To elucidate the pathophysiology of the dyslipidemia in subjects
with abdominal obesity, we recently performed lipoprotein
kinetic studies in 46 middle-aged well-phenotyped men and
women with abdominal obesity and additional cardiometabolic
risk factors to clarify determinants of plasma triglyceride
concentration (Borén et al., 2015). The results are summarized
in Figure 4. The concentration of triglycerides in plasma is
determined by the balance between synthesis and removal
of VLDL1-TG. Thus, dual metabolic defects are required to
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FIGURE 4 | The dysregulation of the VLDL1-TG and apoAI metabolism
in obese subjects. The plasma triglycerides are determined by the balance
between synthesis and removal of VLDL1-TG, illustrated by a Synthesis
pathway and a Clearance pathway. The Synthesis pathway includes liver fat
and total fat mass, the two independent predictors of VLDL1–triglyceride
secretion rate. In the Clearance pathway, plasma concentration of the LPL
inhibitor apoC-III was tightly linked with plasma TG and catabolism of
VLDL1-TG. In addition, apo-CIII was closely related to plasma TG
concentration (dotted arrow). This indirect effect of apoC-III on plasma
triglycerides is likely explained by effect(s) of apoC-III beyond LPL-independent
pathways of triglyceride metabolism (Huard et al., 2005; Sacks et al., 2011).
Increased plasma triglycerides are associated with increased HDL catabolism
(Pont et al., 2002; Ooi et al., 2005; Chan et al., 2009). Thus, increased plasma
triglycerides are closely associated with decreased HDL cholest erol (Verges
et al., 2014). Figure modified from Borén et al. (2015). **p < 0.01; ***p < 0.001.
produce hypertriglyceridemia in obese subjects (Taskinen et al.,
2011). To illustrate this, two pathways are shown; a Synthesis
pathway and a Clearance pathway. The Synthesis pathway
include liver fat and total fat mass since these remained
independent predictors of VLDL1–triglyceride secretion rate in
a stepwise multivariable regression analysis. In the Clearance
pathway, plasma concentration of the LPL inhibitor apoC-
III was tightly linked with plasma TG and catabolism of
VLDL1-TG. In addition, apo-CIII was closely related to plasma
TG concentration. This indirect effect of apoC-III on plasma
triglycerides is likely explained by effect(s) of apoC-III beyond
LPL-independent pathways of triglyceride metabolism (Huard
et al., 2005; Sacks et al., 2011).
HDL cholesterol is closely associated with diabetic
dyslipidemia and abdominal obesity (Verges et al., 2014),
and low HDL cholesterol is strongly associated with increased
cardiovascular risk (Ninomiya et al., 2004). Pharma industry
has therefore developed drugs that increase HDL cholesterol.
However, clinical studies with these agents have not been
successful, and the causative role of HDL is therefore questioned.
This indicates that low HDL cholesterol is more a marker
of an atherogenic lipoprotein profile. In vivo kinetic studies
performed in abdominally obese individuals have shown that
low plasma concentration of HDL cholesterol is the consequence
of increased HDL catabolism (Pont et al., 2002; Ooi et al., 2005;
Chan et al., 2009), and increased plasma triglycerides is closely
associated with decreased HDL cholesterol (Verges et al., 2014).
Interestingly, when comparing the Synthesis pathway and
the Clearance pathway, indices of catabolism were stronger
predictors of plasma triglycerides than parameters of secretion. In
a multivariable regression model, VLDL1-TG kinetics explained
76% of the variation in the total plasma triglycerides. Kinetic
parameters of VLDL1-TG secretion explained 19–20% only
of the variation in plasma triglyceride concentrations in the
study subjects. Thus, in subjects with abdominal obesity and
dyslipidemia, the VLDL1-triglyceride clearance is a stronger
determinant of the plasma triglyceride concentration than
increased secretion of VLDL1 particles. This finding may support
combination therapies in subjects with abdominal obesity and
dyslipidemia affecting both secretion and catabolism of VLDL1-
TG. The results further support apoC-III as a key target for
reducing residual cardiovascular risk.
LIVER FAT ACCUMULATION AND CVD
The observed associations between liver fat plasma triglycerides
are in line with earlier studies showing that liver fat content
is closely related to triglyceride secretion in different settings
and populations (Chan et al., 2010; Taskinen et al., 2011) and
a better predictor of triglyceride secretion than intra-abdominal
fat (Fabbrini et al., 2009; Magkos et al., 2010). It is also clinically
important because of the worrisome increase of non-alcoholic
fatty liver disease (NAFLD), defined as hepatic fat accumulation
that exceeds 5% of liver weight in individuals who do not
consume significant amounts of alcohol (Neuschwander-Tetri
and Caldwell, 2003; Vernon et al., 2011). Approximately 25%
of adults have NAFLD, and its prevalence increases to 70–
90% among adults with obesity or type 2 diabetes (Ray, 2013).
Even though NAFLD may progress to severe liver diseases,
the most common cause of death in patients with NAFLD
is CVD. Several epidemiological studies indicate that NAFLD
is not merely a marker of CVD, but may also be actively
involved in its pathogenesis (Targher et al., 2008). Thus, the
finding that NAFLD is closely linked to overproduction to of
VLDL1-TG that drives an atherogenic dyslipidemia characterized
with hypertriglyceridemia, HDL-cholesterol, and postprandial
hyperlipidemia provide an important explanation for this and
indicates that novel treatments reducing liver fat accumulation
might be important in preventing CVD (Boren et al., 2013).
CONCLUSION
Lipid homeostasis is essential for human health but elevated lipid
levels are a risk factor for atherosclerosis and thus can lead to
symptomatic CVD. Increased lipid levels can be caused by either
increased secretion of atherogenic lipoproteins, and/or impaired
clearance of lipoproteins from the circulation. The use of in vivo
kinetic studies using stable isotopes and mass spectrometry
in combination with the development of mathematical models
has been critical in advancing understanding of normal and
dysregulated lipidmetabolism. However, kinetic studies are time-
consuming, expensive and require a high level of expertise.
Thus, they are limited to rather few research groups. Future,
development will hopefully enable us to optimize the protocols
and increase the statistical power, in particular when data are
sparse (Denti et al., 2009; Largajolli et al., 2012).
Also, combining kinetic studies with advanced modeling,
as genome-scale metabolic modeling (Mardinoglu and Nielsen,
2015; O’Brien et al., 2015), might provide even deeper
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understanding of the metabolic changes and clarify the
underlying metabolic perturbations in the occurrence of
metabolism related disorders. Genome-scale metabolic models
(GEMs) are the collection of the biochemical reactions and
associated protein-coding genes, and provide a scaffold for
integration of the fluxomics as well as other omics data
e.g., proteomics, transcriptomics, metabolomics, and lipidomics.
Recently, a functional GEM for the hepatocytes in liver tissue has
been reconstructed (Mardinoglu et al., 2014) and its use together
with the kinetic studies may provide detailed knowledge for
understanding the relationship between the genotype-phenotype
in different clinical conditions.
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